Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring — A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application

International Journal of Cardiology

Volumn 226, Issue , 2017, Pages 93-102

  Tomaniak, Mariusz ^a   Gąsecka, Aleksandra ^a   Filipiak, Krzysztof J ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antiplatelet agents; Biomarkers; Cardiovascular diseases; Microparticles; Microvesicles; Pharmacotherapy individualization

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CELL FUNCTION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; EVIDENCE BASED PRACTICE; FLOW CYTOMETRY; GOLD STANDARD; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE MICROPARTICLE; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STENT THROMBOSIS; THROMBOSIS PREVENTION; TRANSLATIONAL RESEARCH; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; FORECASTING; HEMORRHAGE; METABOLISM; PROCEDURES; RISK FACTOR; TRENDS;

BIOMARKERS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; FORECASTING; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 84992509196     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.10.007     Document Type: Review

References (80)

1. [1] Rautou, P.E., Vion, A.C., Amabile, N., Chironi, G., Simon, A., Tedgui, A., et al. Microparticles, vascular function, and atherothrombosis. Circ. Res. 109 (2011), 593–606.
2. [2] Morel, O., Pereira, B., Averous, G., Faure, A., Jessel, L., Germain, P., et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis 204 (2009), 636–641.
3. [3] van der Pol, E., Böing, A.N., Gool, E.L., Nieuwland, R., Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J. Thromb. Haemost. 14 (2016), 48–56.
4. [4] Lacroix, R., Judicone, C., Poncelet, P., Robert, S., Arnaud, L., Sampol, J., et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J. Thromb. Haemost. 10 (2012), 437–446.
5. [5] Arraud, N., Gounou, C., Turpin, D., Brisson, A.R., Fluorescence triggering: a general strategy for enumerating and phenotyping extracellular vesicles by flow cytometry. Cytometry Part A, 2015, 10.1002/cyto.a.22669.
6. [6] Robert, S., Lacroix, R., Poncelet, P., Harhouri, K., Bouriche, T., Judicone, C., et al. High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles—brief report. Arterioscler Thromb. Vasc. Biol. 32 (2012), 1054–1058.
7. [7] Hjuler Nielsen, M., Beck-Nielsen, H., Nørgaard Andersen, M., Handberg, A., A flow cytometric method for characterization of circulating cell-derived microparticles in plasma. J. Extracell. Vesicles. 3 (2014), 20795–20807.
8. [8] Melo, S.A., Luecke, L.B., Kahlert, C., Fernandez, A.F., Gammon, S.T., Kaye, J., et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523 (2015), 177–182.
9. [9] van der Pol, E., Böing, A.N., Harrison, P., Sturk, A., Nieuwland, R., et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 64 (2012), 676–705.
10. [10] Barteneva, N.S., Fasler-Kan, E., Bernimoulin, M., Stern, J.N., Ponomarev, E.D., Duckett, L., et al. Circulating microparticles: square the circle. BMC Cell. Biol., 14, 2013, 23.
11. [11] Yuana, Y., Sturk, A., Nieuwland, R., Extracellular vesicles in physiological and pathological conditions. Blood Rev. 27 (2013), 31–39.
12. [12] Connor, D.E., Exner, T., Ma, D.D., Joseph, J.E., The majority of circulating platelet derived microparticles fail to bind annexin V, lack phospholipid procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb. Haemost. 103 (2010), 1044–1052.
13. [13] Aleman, M.M., Gardiner, C., Harrison, P., Wolberg, A.S., et al. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J. Thromb. Haemost. 9 (2011), 2251–2261.
14. [14] Van Der Meijden, P.E., Van Schilfgaarde, M., Van Oerle, R., Renne, T., ten Cate, H., Spronk, H.M., et al. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J. Thromb. Haemost. 10 (2012), 1355–1362.
15. [15] Linden, M.D., Jackson, D.E., Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int. J. Biochem. Cell Biol. 42 (2010), 1762–1766.
16. [16] Bernal-Mizrachi, L., Jy, W., Jimenez, J.J., Pastor, J., Mauro, L.M., Horstman, L.L., et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am. Heart J. 145 (2003), 962–970.
17. [17] Suades, R., Padró, T., Alonso, R., Mata, P., Badimon, L., Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb. Haemost. 110 (2013), 366–377.
18. [18] Stępień, E., Stankiewicz, E., Zalewski, J., Number of microparticles generated during acute myocardial infarction and stable angina correlates with platelet activation. Arch. Med. Res. 43 (2012), 31–35.
19. [19] Biasucci, L.M., Porto, I., Vito, L.D.I., De Maria, G.L., Leone, A.M., Tinelli, G., et al. Differences in microparticle release in patients with acute coronary syndrome and stable angina. Circ. J. 76 (2012), 2174–2182.
20. [20] Li, P., Qin, C., Elevated circulating VE-cadherin + CD144 + endothelial microparticles in ischemic cerebrovascular disease. Thromb. Res. 135 (2015), 375–381.
21. [21] Chen, Y., Xiao, Y., Lin, Z., Xiao, X., He, C., Bihl, J.C., et al. The role of circulating platelets microparticles and platelet parameters in acute ischemic stroke patients. J. Stroke Cerebrovasc. Dis. 24 (2015), 2313–2320.
22. [22] Tan, K.T., Tayebjee, M.H., Lynd, C., Blann, A.D., Lip, G.Y., Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann. Med. 37 (2005), 61–67.
23. [23] Rank, A., Nieuwland, R., Delker, R., Kohler, A., Toth, B., Pihusch, V., et al. Cellular origin of platelet-derived microparticles in vivo. Thromb. Res. 126 (2010), 255–259.
24. [24] Sarlon-Bartoli, G., Bennis, Y., Lacroix, R., Piercecchi-Marti, M.D., Bartoli, M.A., Arnaud, L., et al. Plasmatic level of leukocyte-derived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis. J. Am. Coll. Cardiol. 62 (2013), 1436–1441.
25. [25] Wekesa, A.L., Cross, K.S., O'Donovan, O., Dowdall, J.F., O'Brien, O., Doyle, M., et al. Predicting carotid artery disease and plaque instability from cell-derived microparticles. Eur. J. Vasc. Endovasc. Surg. 48 (2014), 489–495.
26. [26] Zhou, B.D., Guo, G., Zheng, L.M., Zu, L.Y., Gao, W., Microparticles as novel biomarkers and therapeutic targets in coronary heart disease. Chin. Med. J. 128 (2015), 267–272.
27. [27] França, C.N., de Oliveira Izar, M.C., do Amaral, J.B., Tegani, D.M., Fonseca, F.A.H., Microparticles as potential biomarkers of cardiovascular disease. Arq Bras Cardiol 104 (2015), 169–174.
28. [28] Ueba, T., Nomura, S., Inami, N., Plasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. J. Atheroscler. Thromb. 17 (2010), 342–349.
29. [29] Nozaki, T., Sugiyama, S., Koga, H., Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J. Am. Coll. Cardiol. 54 (2009), 601–608.
30. [30] Sinning, J.M., Losch, J., Walenta, K., Bohm, M., Nickenig, G., Werner, N., Circulating CD31 +/Annexin V + microparticles correlate with cardiovascular outcomes. Eur. Heart J. 32 (2011), 2034–2041.
31. [31] Giannopoulos, G., Oudatzis, G., Paterakis, G., Red blood cell and platelet microparticles in myocardial infarction patients treated with primary angioplasty. Int. J. Cardiol. 176 (2014), 145–150.
32. [32] Lee, S.T., Chu, K., Jung, K.H., Circulating CD62E + microparticles and cardiovascular outcomes. PLoS One, 7, 2012, e35713.
33. [33] Faille, D., Frere, C., Cuisset, T., Quilici, J., Moro, P.J., Morange, P.E., PE, et al. CD11b + leukocyte microparticles are associated with high-risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. J. Thromb. Haemost. 9 (2011), 1870–1873.
34. [34] Min, P.K., Cho, M., Hong, S.Y., Circulating microparticles and coronary plaque components assessed by virtual histology intravascular ultrasound of the target lesion in patients with stable angina. Advanced help abstract. PLoS One, 11, 2016, e0148128.
35. [35] Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Samura, T.A., Berezina, T.A., The predictive role of circulating microparticles in patients with chronic heart failure. BBA Clin. 3 (2015), 18–24.
36. [36] Adamski, P., Kozinski, M., Ostrowska, M., Fabiszak, T., Navarese, E.P., Paciorek, P., et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb. Haemost. 112 (2014), 224–242.
37. [37] Bulut, D., Becker, V., Muegge, A., Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can. J. Physiol. Pharmacol. 89 (2011), 239–244.
38. [38] Duarte, R.C., Gonçalves, L.H., Campos, F.M., Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus. Blood Coagul. Fibrinolysis 26 (2015), 123–130.
39. [39] Lubsczyk, B., Kollars, M., Hron, G., Kyrle, P.A., Weltermann, A., Gartner, V., Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans. Eur. J. Clin. Investig. 40 (2010), 477–482.
40. [40] Shirafuji, T., Hamaguchi, H., Kanda, F., Measurement of platelet derived microparticle levels in the chronic phase of cerebral infarction using an enzyme-linked immunosorbent assay. Kobe J. Med. Sci. 54 (2008), E55–E61.
41. [41] Ryu, J.H., Kim, S.J., Clopidogrel effectively suppresses endothelial microparticle generation induced by indoxyl sulfate via inhibition of the p38 mitogen-activated protein kinase pathway. Blood Purif. 32 (2011), 186–194.
42. [42] França, C.N., Pinheiro, L.F., Izar, M.C., Brunialti, M.K., Salomao, R., Bianco, H.T., et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ. J. 76 (2012), 729–736.
43. [43] Kafian, S., Mobarrez, F., Wallén, H., Samad, B., Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets 26 (2015), 467–473.
44. [44] Price, M.J., Berger, P.B., Teirstein, P.S., Tanguay, J.F., Angiolillo, D.J., Spriggs, D., et al. Standard- vs high-doseclopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305 (2011), 1097–1105.
45. [45] Trenk, D., Stone, G.W., Gawaz, M., Kastrati, A., Angiolillo, D.J., Muller, U., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J. Am. Coll. Cardiol. 59 (2012), 2159–2164.
46. [46] Collet, J.P., Cuisset, T., Range, G., Cayla, G., Elhadad, S., Pouillot, C., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367 (2012), 2100–2109.
47. [47] Kalantzi, K.I., Dimitriou, A.A., Goudevenos, J.A., Tselepis, A.D., The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. Platelets 23 (2012), 121–131.
48. [48] Skeppholm, M., Mobarrez, F., Malmqvist, K., Wallen, H., Platelet derived microparticles during and after acute coronary syndrome. Thromb. Haemost. 107 (2012), 1122–1129.
49. [49] Behan, M.W., Fox, S.C., Heptinstall, S., Storey, R.F., Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 16 (2005), 73–80.
50. [50] Judge, H.M., Buckland, R.J., Sugidachi, A., et al. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 19 (2008), 125–133.
51. [51] https://clinicaltrials.gov/ct2/show/NCT02071966.
52. [52] Judge, H.M., Buckland, R.J., Holgate, C.E., Storey, R.F., Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets 16 (2005), 398–407.
53. [53] Morel, O., Hugel, B., Jesel, L., et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J. Thromb. Haemost. 2 (2004), 1118–1126.
54. [54] Goto, S., Tamura, N., Li, M., Handa, M., Ikeda, Y., Handa, S., et al. Different effects of various anti-GPIIb-IIIa agents on shear induced platelet activation and expression of procoagulant activity. J. Thromb. Haemost. 1 (2003), 2022–2030.
55. [55] Yeh, C.H., Peng, H.C., Huang, T.F., Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood 92 (1998), 3268–3276.
56. [56] Craft, J.A., Marsh, N.A., Increased generation of platelet-derived microparticles following percutaneous transluminal coronary angioplasty. Blood Coagul. Fibrinolysis 14 (2003), 719–728.
57. [57] Tantry, U.S., Bonello, L., Aradi, D., Price, M.J., Jeong, Y.H., Angiolillo, D.J., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62 (2013), 2261–2273.
58. [58] Siller-Matula, J.M., Trenk, D., Schror, K., Gawaz, M., Kristensen, S.D., Storey, R.F., et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc. Interv. 6 (2013), 1111–1128.
59. [59] Komosa, A., Siller-Matula, J.M., Kowal, J., Lesiak, M., Siniawski, A., Maczynski, M., et al. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: plavix and generic-Egitromb. Platelets 26 (2015), 43–47.
60. [60] Sibbing, D., Braun, S., Morath, T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53 (2009), 849–856.
61. [61] Geisler, T., Zurn, C., Simonenko, R., Rapin, M., Kraibooj, H., Kilias, A., et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur. Heart J. 31 (2010), 59–66.
62. [62] Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., et al. Ticagrelor versus clopidogrelin patients with acute coronary syndromes. N. Engl. J. Med. 361 (2009), 1045–1057.
63. [63] Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357 (2007), 2001–2015.
64. [64] Jakubowski, J.A., Riesmeyer, J.S., Close, S.L., et al. TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc. Ther. 30 (2012), 174–182.
65. [65] Navarese, E.P., Verdoia, M., Schaffer, A., et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. Q.J.M. 104 (2011), 561–569.
66. [66] Siller-Matula, J.M., Jilma, B., Why have studies of tailored antiplatelet therapy failed so far?. Thromb. Haemost. 110 (2013), 628–631.
67. [67] Aradi, D., Komocsi, A., Price, M.J., et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int. J. Cardiol. 167 (2013), 2140–2148.
68. [68] Siller-Matula, J.M., Gruber, C., Francesconi, M., et al. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin. Sci. 128 (2015), 121–130.
69. [69] Christ, G., Siller-Matula, J.M., Francesconi, M., et al. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open, 4, 2014, e005781.
70. [70] van der Pol, E., Coumans, F.A.W., Grootemaat, A.E., Gardiner, C., Sargent, I.L., Harrison, P., et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J. Thromb. Haemost. 12 (2014), 1182–1192.
71. [71] Yuana, Y., Bertina, B.M., Osanto, S., Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb. Haemost. 105 (2011), 396–408.
72. [72] Yuana, Y., Levels, J., Grootemaat, A., et al. Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation. J. Extracell. Vesicles. 3 (2014), 1–5.
73. [73] Yuana, Y., Nieuwland, R., Protocols to Collect and Prepare Human Blood, Urine, and Saliva for Measurement of Microvesicles. available at: www.metves.eu/output/reports.
74. [74] Böing, A.N., van der Pol, E., Grootemaat, A.E., et al. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J. Extracell. Vesicles., 3, 2014, 10.
75. [75] van der Pol, E., Coumans, F., Varga, Z., Krumrey, M., Nieuwland, R., Innovation in detection of microparticles and exosomes. J. Thromb. Haemost. 11:Suppl. 1 (2013), 36–45.
76. [76] van der Pol, E., Van Gemert, M.J., Sturk, A., et al. Single vs swarm detection of microparticles and exosomes by flow cytometry. J. Thromb. Haemost. 10 (2012), 919–930.
77. [77] Robert, S., Poncelet, P., Lacroix, R., et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first steptowards multicenter studies?. J. Thromb. Haemost. 7 (2009), 190–197.
78. [78] Chandler, W.L., Yeung, W., Tait, J.F., A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer. J. Thromb. Haemost. 9 (2011), 1216–1224.
79. [79] Street, J.M., Barran, P.E., Mackay, C.L., et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J. Transl. Med., 10, 2012, 5.
80. [80] http://www.evflowcytometry.org.